Showing Latest Articles
Allos Therapeutics Reports Second Quarter 2010 Financial Results
Allos Therapeutics, 07/29/2010
Free full text
During the quarter, we continued to build marketplace awareness for FOLOTYN for the treatment of relapsed or refractory PTCL," said Paul L. Berns, president and chief executive officer of Allos Therapeutics. "We believe this represents an important market opportunity for Allos, and we are encouraged by the level of awareness and use of FOLOTYN at this stage of our commercial launch. In addition, we continued to drive our strategic lifecycle development plan for FOLOTYN with the goal of extending its commercial opportunity and building additional shareholder value through potential expanded indications in the U.S. and abroad.
